Additional Data From the Phase 2 Oral Insulin Study Will Be Posted Prior to
and Discussed at the Conference
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced that it will present at
the Rodman & Renshaw 8th Annual Healthcare Conference, taking place on
November 6-8, 2006 at the New York Palace Hotel in New York City. Michael
M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on
Wednesday, November 8, 2006, at 11:40 a.m. Eastern Time. Joining Dr.
Goldberg at the conference will be Ehud Arbit, M.D., V.P., Medical Research
and Steven Dinh, Sc.D., V.P., Research and Technology Development.
The Company will be providing additional data from the recently
completed Phase 2 study with oral insulin. The data will be posted to the
Investor Relations portion of the Emisphere Technologies' website,
http://www.emisphere.com/ir.asp on Wednesday, November 8, 2006, at 8:00
a.m. Eastern Time.
The Rodman and Renshaw presentation will be broadcast live via the
Internet. You may access the presentation by visiting Emisphere
Technologies' website, or directly at:
http://www.wsw.com/webcast/rrshq10/emis/
Please visit either site at least five minutes prior to start time for
instructions. A replay will be available two hours after the presentation,
through December 8, 2006.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit the Emisphere website,
http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 16, 2006.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
http://www.emisphere.com/ir.asp
http://www.wsw.com/webcast/rrshq10/emis
CONTACT:
Stewart Siskind of Emisphere Technologies,
Inc., +1-914-785-4742; or Media: Dan Budwick of BMC
Communications, +1-212-477-9007 ext. 14, for Emisphere
Technologies, Inc.
|
